drugset / Trial / NCT00647400
Adalimumab in Adult Japanese Subjects With Psoriasis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with psoriasis
Timeline
- Start
- 2006-04
- Primary completion
- 2007-09
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | Adalimumab | Monoclonal antibody | 80 mg | Subcutaneous |